ORMP — Oramed Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $171.80m
- $121.19m
- $2.00m
Brief: Oramed Granted U.S. Patent For Oral GLP-1 & Insulin For Diabetes Treatment
Brief: Oramed Completes Patient Enrollment In Pivotal Phase 3 Oral Insulin Study
Brief: Oramed Completes Patient Enrollment In Phase 2 Oral Insulin NASH Trial
U.S. STOCKS ON THE MOVE-Big banks, Ford, General Electric, Intel,
U.S. STOCKS ON THE MOVE-Livent, Nvidia, PPL Corporation, Pfizer, Dollar Tree
U.S. STOCKS ON THE MOVE-Intel, Palantir Technologies, DraftKings, Roku
Cantor sees promising future for Oramed's insulin capsule; initiates
Brief: Oramed Granted Key European Patent For Platform Technology In Oral Delivery Of Proteins
U.S. STOCKS ON THE MOVE-Carnival Corp, Insignia Systems, Scienjoy
Oramed rises as subsidiary signs pre-purchase order for COVID-19 vaccine
Brief: Mymd Pharmaceuticals Investment Company Oravax Medical Signs Cooperation And Purchase Agreement For Initial Pre-Purchase Of 10 Million Doses Of Oral Covid-19 Vaccine To Be Commercialized In Southeast Asia
Brief: Oramed Subsidiary Oravax Medical Signs Deal For An Initial Pre-Purchase Of 10 Mln Doses Of Oral COVID-19 Vaccines With Tan Thanh Holdings To Commercialize In Southeast Asia
Israel's Oramed gets Vietnam pre-order for 10 mln COVID-19 vaccine doses
Brief: Oramed Subsidiary Oravax Reports First Participant Enrolled in Oral COVID-19 Vaccine Trial
Brief: Oramed Pharmaceuticals Appoints Chief Legal Officer
Brief: Oramed to Join MSCI USA Small Cap Index
Brief: Oramed Reaches 75% Enrollment In Phase 3 Oral Insulin Study
Brief: Oramed Subsidiary Oravax Medical And Genomma Lab Internacional Announce Joint Venture To Develop And Commercialize Oral COVID-19 Vaccine In Mexico
Brief: Oramed Announces $50 Million Registered Direct Offering Of Common Stock Priced At-The-Market Under Nasdaq Rules